Vitamin D3 Supplementation in HIV Patients: Effects on IL-6 and CD4 Counts
Summary
This ClinicalTrials.gov record (NCT07553052) registers an interventional study evaluating Vitamin D3 supplementation over 3 months in patients with HIV receiving antiretroviral therapy. The trial will measure Interleukin-6 levels and CD4 counts as primary outcomes to assess the effect of Vitamin D3 on inflammatory markers and immune status. The study is registered with NIH and open to participants meeting HIV and antiretroviral therapy criteria.
“Participants will receive Vitamin D3 supplementation for 3 months.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This is a clinical trial registration entry for a prospective interventional study on ClinicalTrials.gov, not a regulatory rule or guidance document. The study enrolls HIV-positive participants on antiretroviral therapy and administers Vitamin D3 supplementation for 3 months, with Interleukin-6 levels and CD4 counts as measured outcomes.
Affected parties — clinical investigators, trial sponsors, and healthcare providers conducting or referencing HIV adjuvant therapy research — should note this trial is registered and active. The study may inform future clinical practice regarding vitamin D3 adjunctive therapy in HIV management if statistically significant improvements in immune markers are demonstrated.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts
N/A NCT07553052 Kind: NA Apr 27, 2026
Abstract
This study aims to evaluate the effect of Vitamin D3 supplementation on inflammatory markers and immune status in patients with HIV who are receiving antiretroviral therapy. Participants will receive Vitamin D3 supplementation for 3 months. Outcomes including Interleukin-6 levels and CD4 counts will be measured to assess the potential benefits of this intervention.
Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Vitamin D3, Antiretroviral (ARV) medications
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.